Search Result

Pathways Recommended:	Neuronal Signaling JAK/STAT Signaling

Results for "

glucocorticoid receptor signaling

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Glucocorticoid Receptor (13) Akt (1) Androgen Receptor (1) AP-1 (1) Apoptosis (6) Bacterial (2) Calcium Channel (1) COX (1) ERK (2) Estrogen Receptor/ERR (1) Ferroptosis (1) FKBP (1) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) Glutathione Reductase (GR) (1) IKK (1) Interleukin Related (3) Isotope-Labeled Compounds (1) JAK (1) JNK (1) mTOR (1) NF-κB (5) p38 MAPK (2) Phosphodiesterase (PDE) (5) PI3K (1) Progesterone Receptor (1) PROTACs (2) Reactive Oxygen Species (ROS) (1) Reference Standards (3) STAT (1) TNF Receptor (1) Toll-like Receptor (TLR) (2) Transmembrane Glycoprotein (1) Wnt (5) β-catenin (5)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Endocrinology (5) Infection (2) Inflammation/Immunology (13) Metabolic Disease (6) Neurological Disease (9)

By Targets:

Glucocorticoid Receptor (13)

Akt (1)

Androgen Receptor (1)

AP-1 (1)

Apoptosis (6)

Bacterial (2)

Calcium Channel (1)

COX (1)

ERK (2)

Estrogen Receptor/ERR (1)

Ferroptosis (1)

FKBP (1)

FXR (1)

G protein-coupled Bile Acid Receptor 1 (1)

Glutathione Reductase (GR) (1)

IKK (1)

Interleukin Related (3)

Isotope-Labeled Compounds (1)

JAK (1)

JNK (1)

mTOR (1)

NF-κB (5)

p38 MAPK (2)

Phosphodiesterase (PDE) (5)

PI3K (1)

Progesterone Receptor (1)

PROTACs (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (3)

STAT (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (2)

Transmembrane Glycoprotein (1)

Wnt (5)

β-catenin (5)

By Research Areas:

Cancer (6)

Cardiovascular Disease (1)

Endocrinology (5)

Infection (2)

Inflammation/Immunology (13)

Metabolic Disease (6)

Neurological Disease (9)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Glucocorticoid Receptor RGS Protein SGK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-158101

BMS-986365 1 Publications Verification CC-94676	PROTACs Androgen Receptor	Cancer
BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader (DC₅₀ of 10-40 nM). BMS-986365 is capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows no degradation of the close AR family members estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. BMS-986365 can be used for the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-B1060

Methylprednisolone succinate sodium 2 Publications Verification Methylprednisolone hydrogen succinate sodium	Glucocorticoid Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Methylprednisolone succinate (Methylprednisolone hydrogen succinate) sodium is a prodrug of Methylprednisolone (HY-B0260) and glucocorticoid with immunosuppressant and anti-inflammatory activity. Methylprednisolone succinate sodium binds cytosolic glucocorticoid receptors, translocates to nuclei, and modulates target gene transcription. Methylprednisolone succinate sodium alters Bax, Bcl-2, occludin, and ZO-1 expression; attenuates TLR4/NF-κB signaling; suppresses proinflammatory cytokine production and immune cell activation. Methylprednisolone succinate sodium can be used for the research of intracranial haemorrhage, rheumatoid arthritis, multiple sclerosis, preterminal cancer, inflammatory conditions, shock, immediate-type hypersensitivity, acute myocardial ischemia, hypoxic heart muscle damage, and traumatic spinal cord injury .

HY-14930

Mirodenafil SK3530	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .

HY-B1900

Methylprednisolone succinate 2 Publications Verification Methylprednisolone hydrogen succinate	Glucocorticoid Receptor Bacterial Toll-like Receptor (TLR) NF-κB	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Methylprednisolone succinate (Methylprednisolone hydrogen succinate) is a prodrug of Methylprednisolone (HY-B0260) and glucocorticoid with immunosuppressant and anti-inflammatory activity. Methylprednisolone succinate binds cytosolic glucocorticoid receptors, translocates to nuclei, and modulates target gene transcription. Methylprednisolone succinate alters Bax, Bcl-2, occludin, and ZO-1 expression; attenuates TLR4/NF-κB signaling; suppresses proinflammatory cytokine production and immune cell activation. Methylprednisolone succinate can be used for the research of intracranial haemorrhage, rheumatoid arthritis, multiple sclerosis, preterminal cancer, inflammatory conditions, shock, immediate-type hypersensitivity, acute myocardial ischemia, hypoxic heart muscle damage, and traumatic spinal cord injury .

HY-14930A

Mirodenafil dihydrochloride SK-3530 dihydrochloride	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-B1900R

Methylprednisolone succinate (Standard) 1 Publications Verification Methylprednisolone hydrogen succinate (Standard)	Reference Standards Glucocorticoid Receptor Bacterial Toll-like Receptor (TLR) NF-κB	Metabolic Disease Inflammation/Immunology Cancer
Methylprednisolone succinate (Standard) is the analytical standard of Methylprednisolone succinate (HY-B1900). This product is intended for research and analytical applications. Methylprednisolone succinate (Methylprednisolone hydrogen succinate) is a prodrug of Methylprednisolone (HY-B0260) and glucocorticoid with immunosuppressant and anti-inflammatory activity. Methylprednisolone succinate binds cytosolic glucocorticoid receptors, translocates to nuclei, and modulates target gene transcription. Methylprednisolone succinate alters Bax, Bcl-2, occludin, and ZO-1 expression; attenuates TLR4/NF-κB signaling; suppresses proinflammatory cytokine production and immune cell activation. Methylprednisolone succinate can be used for the research of intracranial haemorrhage, rheumatoid arthritis, multiple sclerosis, preterminal cancer, inflammatory conditions, shock, immediate-type hypersensitivity, acute myocardial ischemia, hypoxic heart muscle damage, and traumatic spinal cord injury .

HY-176877

Glucocorticoid receptor/IL-6-IN-2	Glucocorticoid Receptor Interleukin Related	Inflammation/Immunology
Glucocorticoid receptor/IL-6-IN-2 (Compound 36) is a selective dual inhibitor targeting the glucocorticoid receptor (GR) and IL-6 signaling pathway (IC₅₀ values of 40 nM and 19 nM, respectively). Glucocorticoid receptor/IL-6-IN-2 is promising for research of inflammatory diseases like rheumatoid arthritis and asthma .

HY-176876

Glucocorticoid receptor/IL-6-IN-1	Glucocorticoid Receptor Interleukin Related JAK STAT	Inflammation/Immunology
Glucocorticoid receptor/IL-6-IN-1 (Compound 35) is a selective dual inhibitor targeting the glucocorticoid receptor (GR) and IL-6 signaling pathway (IC₅₀ values of 120 nM and 59 nM, respectively). Glucocorticoid receptor/IL-6-IN-1 inhibits IL-6-induced JAK/STAT3 phosphorylation, blocking inflammatory cytokine transcription. Glucocorticoid receptor/IL-6-IN-1 is promising for research of inflammatory diseases like rheumatoid arthritis and asthma .

HY-14930R

Mirodenafil (Standard) SK3530 (Standard)	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Reference Standards	Neurological Disease Inflammation/Immunology Endocrinology
Mirodenafil (Standard) is the analytical standard of Mirodenafil. This product is intended for research and analytical applications. Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .

HY-161520

Glucocorticoid receptor/NF-κB modulator-1	Glucocorticoid Receptor NF-κB	Inflammation/Immunology
Glucocorticoid receptor/NF-κB modulator-1 (Compound 20) is a derivative of ocotillol. Glucocorticoid receptor/NF-κB modulator-1 suppresses the degradation of glucocorticoid receptor (GR) mRNA and GR protein, inhibits the activation of NF-κB signaling pathway. Glucocorticoid receptor/NF-κB modulator-1 downregulates levels of NO, interleukin-6 and tumor necrosis factor-alpha (TNF-α). Glucocorticoid receptor/NF-κB modulator-1 ameliorates sepsis in mouse model .

HY-14930AR

Mirodenafil dihydrochloride (Standard) SK-3530 dihydrochloride (Standard)	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Reference Standards	Neurological Disease Inflammation/Immunology Endocrinology
Mirodenafil (dihydrochloride) (Standard) is the analytical standard of Mirodenafil (dihydrochloride). This product is intended for research and analytical applications. Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .

HY-181014

Glucocorticoid receptor modulator 5	Glucocorticoid Receptor NF-κB AP-1	Inflammation/Immunology
Glucocorticoid receptor modulator 5 (Compound D8) is a selective, orally active **Glucocorticoid receptor** modulator. Glucocorticoid receptor modulator 5 shows extremely high transrepression activity (TR_NF-κB IC₅₀ = 0.0009 μM, TR_AP-1 IC₅₀ = 0.0005 μM). Glucocorticoid receptor modulator 5 exerts its anti-inflammatory activity by interacting directly with the Glucocorticoid receptor signaling pathway. Glucocorticoid receptor modulator 5 significantly alleviates dermatitis and autoimmune hepatitis .

HY-181289

SelDeg51	PROTACs FKBP Glucocorticoid Receptor	Neurological Disease Metabolic Disease
SelDeg51 is a selective FKBP51 PROTAC degrader with a K_d value of 18 nM and a D_max of 90%. SelDeg51 induces proteasomal degradation of FKBP51 via the FKBP51:SelDeg51:VCB ternary complex and reactivates the glucocorticoid receptor signaling pathway. SelDeg51 can be used for research on stress-related mental disorders, chronic pain, and obesity .

HY-119080

CP8754	Progesterone Receptor	Endocrinology Cancer
CP8754 is an orally active, selective human *progesterone receptor* (hPR)** antagonist that blocks progesterone-mediated signaling pathways. CP8754 competitively inhibits the binding of [ ³H]-progesterone to hPR. And in vitro, CP8754 inhibits progesterone-dependent exogenous luciferase and endogenous alkaline phosphatase expression; while in vivo, CP8754 inhibits rabbit endometrial transformation. CP8754 does not significantly bind to human glucocorticoid receptors (hGR), *estrogen receptors* (hER), or rat androgen receptors (rAR)**. CP8754 can be used in the study of progesterone-related diseases such as breast cancer, endometriosis, uterine fibroids, and meningioma, as well as hormone-dependent tumors .

HY-184324

Anti-inflammatory agent 116	NF-κB p38 MAPK Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor COX IKK ERK JNK	Metabolic Disease
Anti-inflammatory agent 116 is an anti-inflammatory agent. Anti-inflammatory agent 116 binds to the p50 subunit and impairs the DNA-binding ability of the p65-p50 heterodimer. Anti-inflammatory agent 116 inhibits the abnormal activation of the NF-κB/MAPK signaling pathway. Anti-inflammatory agent 116 inhibits LPS-induced NO and MtROS production, IL-1β and TNF-α secretion, iNOS and COX-2 expression, phosphorylation of IKK, IκB, p65, p38, ERK and JNK, as well as nuclear translocation of p65. Anti-inflammatory agent 116 alleviates sepsis-associated acute liver injury in mice. Anti-inflammatory agent 116 can be used for the research of sepsis-associated acute liver injury .

HY-14930S

Mirodenafil-d7 SK3530-d₇	Isotope-Labeled Compounds Glucocorticoid Receptor Wnt Apoptosis β-catenin Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Inflammation/Immunology
Mirodenafil-d₇ (SK3530-d₇) is the deuterium labeled Mirodenafil (HY-14930). Mirodenafil (SK3530) is an orally active, potent, reversible, and selective?phosphodiesterase?5 (PDE5)?inhibitor. Mirodenafil is a?glucocorticoid receptor?(GR)?modulator Mirodenafil activates the?Wnt/β-catenin?signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

Cat. No.	Product Name	Chemical Structure

HY-14930S

Mirodenafil-d7
Mirodenafil-d₇ (SK3530-d₇) is the deuterium labeled Mirodenafil (HY-14930). Mirodenafil (SK3530) is an orally active, potent, reversible, and selective?phosphodiesterase?5 (PDE5)?inhibitor. Mirodenafil is a?glucocorticoid receptor?(GR)?modulator Mirodenafil activates the?Wnt/β-catenin?signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).

Mirodenafil-d7

Mirodenafil-d₇ (SK3530-d₇) is the deuterium labeled Mirodenafil (HY-14930). Mirodenafil (SK3530) is an orally active, potent, reversible, and selective?phosphodiesterase?5 (PDE5)?inhibitor. Mirodenafil is a?glucocorticoid receptor?(GR)?modulator Mirodenafil activates the?Wnt/β-catenin?signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks